The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer (See paper)

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer (See paper)

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis (See paper)

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer (See paper)

Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-Resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns (See paper)

Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer  (See paper)

Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer (See paper)

The In Vitro Stability of Circulating Tumour DNA (See paper)

A new method to select the right treatment for advanced prostate cancer

Liquid Biopsy-Based Androgen Receptor Alterations Associated With Advanced Prostate Cancer Outcomes 

Liquid Biopsy Shows Promise in Prostate Cancer Across Multiple Biomarkers

ESMO 2019 Congress - ProBio An outcome adaptive multi arm open label multiple assignment randomised controlled biomarker driven trial in patients with metastatic castration resistant prostate cancer.